Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer - Wikidata - awgldk - TriplyDB

Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer

Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer

http://www.wikidata.org/entity/Q33628784

about

Epidemiology and management of common pulmonary diseases in older persons Preliminary Development and Evaluation of an Algorithm to Identify Breast Cancer Chemotherapy Toxicities Using Electronic Medical Records and Administrative Data.Strengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trials.Evaluation of the efficacy and safety of the combination of gemcitabine and nedaplatin for elderly patients with advanced non-small-cell lung cancer.Incidence of Neutropenia in Veterans Receiving Lung Cancer Chemotherapy: A Comparison of Administrative Coding and Electronic Laboratory Data.Effectiveness and safety of chemotherapy combined with dendritic cells co-cultured with cytokine-induced killer cells in the treatment of advanced non-small-cell lung cancer: a systematic review and meta-analysis.Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509.Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older: A retrospective analysis.Second-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: evaluation of performance status and health-related quality of life.Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare.Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.Geographic variation in the use of adjuvant therapy among elderly patients with resected non-small cell lung cancer Treatment of advanced lung cancer in the elderly.Chemotherapy treatment decision making by professionals and older patients with cancer: a narrative review of the literature.Treatment of elderly patients with stage IV non-small-cell lung cancer.Standard radical gastrectomy in octogenarians and nonagenarians with gastric cancer: are short-term surgical results and long-term survival substantial?Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011).Therapeutic vaccination for non-small-cell lung cancer: a meta-analysis.Lung cancer chemotherapy decisions in older patients: the role of patient preference and interactions with physicians.Toxicity-Related Factors Associated With Use of Services Among Community Oncology Patients.Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer.A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.The effects of advanced age and serum α1 -acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients.Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.Re: personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207†.Encouraging results in older patients receiving chemotherapy: a retrospective analysis of treatment guideline adherence in daily practice.Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy.The addition of chemotherapy to radiation therapy improves survival in elderly patients with stage III non-small cell lung cancer.Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology.First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly 'unfrail' patients with advanced non-small-cell lung cancer: a multicenter phase II study.Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer.

P2860

Q28397465-2C395D98-9EAA-4604-8C0E-4749E58FF6E1 Q30845285-5E12256F-5029-45B5-BACE-921CA126594D Q31050197-330D4BEE-2896-47E9-A380-4AA01BBB57B3 Q33398466-28BA7434-5203-4E5C-BAC3-B4CA02EEFF83 Q33557215-6BB5355F-660C-4FEF-9309-1172F2E5BE82 Q34277777-6DBB5112-22EC-4F6D-ABFD-72719888E648 Q34786733-E8898060-1C0F-46BF-961C-A2A1E8F60BBD Q35058608-31843568-C72E-4330-AE95-EFF437B36899 Q35179355-B09912A4-E46E-482C-BA97-416572C2AA4C Q35802325-508450AC-4497-4C63-B110-C74EF3BB54BB Q35925280-CE809567-0A8B-4E14-BC5A-5FAFDE81DA23 Q36304283-16A402C1-6E85-4658-9740-3699920D5130 Q36368864-E39EC5DE-D8B6-4CB7-9410-849217D986A0 Q36774403-F6FDD1D6-F1E5-4D24-B44F-0229773B047A Q37876082-AB073BB7-8477-4B78-86E1-DB61AC506CCD Q37939963-CF83A836-7BEE-4537-BD76-2B8ABD330C6A Q37965641-E08E6E57-D098-477D-9709-9FE1E84D072C Q37986614-227F4B8C-EC92-4643-ACDE-D3508D3E64A0 Q39043072-D05CF6D5-48EC-4266-B71E-CE1B4903F884 Q39227338-21C6A430-171B-4BA4-937D-B4410CB1FD06 Q39251171-AFD09F50-3478-4067-9BC5-9A515F709BE3 Q40097166-ED8579AC-C4A4-4F30-8219-87D4FFA97609 Q40990450-895BA4D7-27C6-498D-9C38-33D6A60849C8 Q41537638-5529C706-F932-438D-B224-369030FFFB99 Q41560445-383278F7-55A3-4217-AA9A-67BD82046580 Q42656439-9D594BDC-B22C-45FE-B56E-5426F36E0ED8 Q42766829-201C4D75-F4BF-4E19-8302-27B0BA9E437B Q43026530-4AFDEAD1-2EF8-4B17-B612-309BF11ABB2F Q44685863-E89FEC24-D424-426E-A9A6-F9574F2A4831 Q46653169-5ABC24C7-FDDF-41CC-A146-1BD10AC12FA8 Q48544302-D0F12E52-7611-4316-84E6-AFF37E6CDFF3 Q50078570-4AB38609-DFF2-4AB3-8B5F-0BF0E2E93A7C Q53061916-5F391D41-828F-4B82-AB2D-569E4F1A27AB Q53158825-28F0DE65-DCD3-4669-856C-79D744304CA7 Q54308862-DC6C4124-CD85-4E66-A77B-7AFAEADF4D48

P2860

Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer

http://www.wikidata.org/entity/Q33628784

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Adverse events among the elder ...... ced non-small-cell lung cancer

@ast

Adverse events among the elder ...... ced non-small-cell lung cancer

@en

type

label

Adverse events among the elder ...... ced non-small-cell lung cancer

@ast

Adverse events among the elder ...... ced non-small-cell lung cancer

@en

prefLabel

Adverse events among the elder ...... ced non-small-cell lung cancer

@ast

Adverse events among the elder ...... ced non-small-cell lung cancer

@en

P1433

Q33628784-538AE3D9-A2C9-40E6-AC08-9F21D3DEC463

P1476

Q33628784-A29C33CF-7A42-4D6C-9E32-0E97412CBE8E

P2093

Q33628784-0FF61B36-BC48-4A60-887C-0D853E057F50

Q33628784-461E54FA-8F43-40C1-BD6E-878F5CD68D70

Q33628784-515B895F-13F7-4245-B533-A4512BDD6FB7

Q33628784-5FB6C804-3E2E-465B-BFB2-11C0F19D3EC6

Q33628784-6DD16342-247A-4D62-8A09-44B47F82C2BE

Q33628784-7C570E11-7996-4696-815E-006FC8042A46

Q33628784-89304F34-337B-41A3-9CAD-745911F3C28B

Q33628784-A10B89CB-BC8D-4A81-85FF-B96454FF7186

Q33628784-B89E505D-4E51-4D82-A8EC-756B226030FA

P2860

Q33628784-1CC32442-8655-438C-A73F-35E5913CEADF

Q33628784-263AC93E-8767-4D20-B3AB-926206136108

Q33628784-42723F15-7DD7-476D-91BD-8AD79650EF1C

Q33628784-4325B4C4-447A-4378-B870-1FCCE4FEBD0E

Q33628784-4641BD61-D5EA-4E5F-B7F4-FDCDF681A5E7

Q33628784-949A9A45-DB1B-40BB-B589-1F01369F3C1F

Q33628784-97A39F73-1D80-4556-AD7E-CD1E795AF3BD

Q33628784-AA011A37-DE4B-4615-BBC6-EC51189E497E

Q33628784-C4DA71CB-3ED3-4F9D-9634-9C3C2E21ED9E

Q33628784-CF60F63A-B227-4942-8E18-49B20882CB6E

P304

Q33628784-5185821B-494E-46FD-9456-C17010214C1B

P31

Q33628784-4A96F825-1A0A-418F-9627-E3E7CEC60CA7

P356

Q33628784-700A2BCA-E54E-4A31-B14C-FE75A8B78107

P407

Q33628784-6F1D7978-B7C9-4B43-A0C2-9C150F5072AA

P433

Q33628784-85760B9E-A691-4B48-92F3-17451EC67214

P478

Q33628784-37DFE281-740C-47DD-A1C9-63E644680D87

P50

Q33628784-5AA5297C-8688-49A7-A44D-654F016505EF

Q33628784-EACD96B7-9AC3-4AF8-8DE7-6CE4B72C748B

P577

Q33628784-3F0A2EFA-A968-48CA-A9C8-5B2861B28DBD

P698

Q33628784-5E837BD7-859A-4D01-B1E0-C67032569224

P921

Q33628784-1EF90A19-5D71-4DDB-82CA-C95DF10A3438

P932

Q33628784-13500942-54CB-42B2-9F61-21B277638C22

P356

JCO.2009.23.8485

P1433

Journal of Clinical Oncology

P1476

Adverse events among the elder ...... ced non-small-cell lung cancer

@en

P2093

Catarina I Kiefe

http://www.w3.org/2001/XMLSchema#string

Daniela C Moga

http://www.w3.org/2001/XMLSchema#string

David P Harrington

http://www.w3.org/2001/XMLSchema#string

Dee W West

http://www.w3.org/2001/XMLSchema#string

Jane C Weeks

http://www.w3.org/2001/XMLSchema#string

Jane F Pendergast

http://www.w3.org/2001/XMLSchema#string

Katherine L Kahn

http://www.w3.org/2001/XMLSchema#string

Robert B Wallace

http://www.w3.org/2001/XMLSchema#string

Robert H Fletcher

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Predictive margins with survey data.

The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study.

The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.

Influence of age and comorbidities on the chemotherapeutic management of lung cancer.

An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer.

Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence.

Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials.

Health state utilities for non small cell lung cancer.

Differences in initial treatment patterns and outcomes of lung cancer in the elderly.

P304

620-627

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.23.8485

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth A Chrischilles

S. Yousuf Zafar

P577

2009-12-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20038726

http://www.w3.org/2001/XMLSchema#string

P921

P932

2815997

http://www.w3.org/2001/XMLSchema#string